Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / SHS
-
Total 13F shares
-
1,051,132
-
Share change
-
+131,806
-
Total reported value
-
$6,519,000
-
Price per share
-
$6.20
-
Number of holders
-
10
-
Value change
-
+$851,792
-
Number of buys
-
5
-
Number of sells
-
2
Institutional Holders of GALMED PHARMACEUTICALS LTD - SHS (GLMD) as of Q2 2017
As of 30 Jun 2017,
GALMED PHARMACEUTICALS LTD - SHS (GLMD) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,051,132 shares.
The largest 10 holders included
683 Capital Management, LLC, Park West Asset Management LLC, P.A.W. CAPITAL CORP, MORGAN STANLEY, GLG LLC, GRT CAPITAL PARTNERS L.L.C., CapWealth Advisors, LLC, UBS Group AG, REILLY FINANCIAL ADVISORS, LLC, and Tower Research Capital LLC (TRC).
This page lists
10
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.